Handelsbanken Fonder Ab Bei Gene, Ltd. Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

A detailed history of Handelsbanken Fonder Ab transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 26,370 shares of BGNE stock, worth $4.76 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

26,370

Previous 26,370 -0.0%

Holding current value

$4.76 Million

Previous $3.76 Million 57.36%

% of portfolio

0.02%

Previous 0.02%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$129.52 - $174.32 $727,384 - $978,981	5,616 Added 27.06%	26,370 $3.76 Million
Q1 2024 May 13, 2024	SELL	$141.8 - $181.47 $74,586 - $95,453	-526 Reduced 2.47%	20,754 $3.25 Million
Q4 2023 Feb 01, 2024	SELL	$158.67 - $201.58 $1.04 Million - $1.32 Million	-6,529 Reduced 23.48%	21,280 $3.84 Million
Q3 2023 Oct 19, 2023	BUY	$179.87 - $225.13 $71,948 - $90,052	400 Added 1.46%	27,809 $5 Million
Q2 2023 Aug 02, 2023	BUY	$178.3 - $266.78 $71,320 - $106,711	400 Added 1.48%	27,409 $4.89 Million
Q1 2023 Apr 28, 2023	BUY	$215.53 - $274.5 $407,351 - $518,805	1,890 Added 7.52%	27,009 $5.82 Million
Q4 2022 Feb 07, 2023	BUY	$125.51 - $229.3 $409,915 - $748,893	3,266 Added 14.95%	25,119 $5.53 Million
Q3 2022 Oct 27, 2022	BUY	$131.8 - $202.24 $270,585 - $415,198	2,053 Added 10.37%	21,853 $2.95 Million
Q2 2022 Aug 03, 2022	BUY	$121.11 - $216.05 $278,553 - $496,915	2,300 Added 13.14%	19,800 $3.21 Million
Q1 2022 May 11, 2022	BUY	$146.52 - $269.56 $146,520 - $269,560	1,000 Added 6.06%	17,500 $3.3 Million
Q4 2021 Feb 08, 2022	SELL	$248.56 - $389.34 $695,968 - $1.09 Million	-2,800 Reduced 14.51%	16,500 $4.47 Million
Q3 2021 Nov 10, 2021	BUY	$249.6 - $403.14 $174,720 - $282,198	700 Added 3.76%	19,300 $7.01 Million
Q2 2021 Aug 03, 2021	BUY	$292.75 - $367.01 $380,575 - $477,113	1,300 Added 7.51%	18,600 $6.38 Million
Q1 2021 Apr 29, 2021	BUY	$260.64 - $382.12 $443,088 - $649,604	1,700 Added 10.9%	17,300 $6.02 Million
Q4 2020 Feb 11, 2021	BUY	$221.31 - $316.61 $796,716 - $1.14 Million	3,600 Added 30.0%	15,600 $4.03 Million
Q2 2020 Aug 13, 2020	BUY	$123.9 - $195.41 $1.49 Million - $2.34 Million	12,000 New	12,000 $2.26 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Bei Gene, Ltd. Transaction History